Gut inflammation in response to injury: Potential target for therapeutic intervention

Recent Patents on Anti-Infective Drug Discovery

Volumn 6, Issue 3, 2011, Pages 206-215

  Akhtar, Suhail ^a,c,d   Choudhry, Mashkoor A ^a,b,c,d  

^a Departments of Surgery   (United States)

^b Immunology/Microbiology   (United States)

^c Alcohol Research Program   (United States)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Burn; Chemokines; Cytokines; Intestine; Neutrophils; Superoxide anion

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CRYOPYRIN; ENZYME INHIBITOR; GELATINASE INHIBITOR; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; INTERLEUKIN 6; ISOXAZOLE; LEUKOCYTE ELASTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1 INHIBITOR; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIK 75; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; WORTMANNIN;

ANTIBODY AFFINITY; CELL MIGRATION; CELL PROLIFERATION; COLITIS; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG PROTEIN BINDING; ENTERITIS; ENZYME ACTIVATION; ERRATUM; HUMAN; INTESTINE INJURY; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; PATENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TISSUE INJURY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG DELIVERY SYSTEMS; GASTROENTERITIS; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATION; NEUTROPHIL ACTIVATION; SIGNAL TRANSDUCTION;

EID: 80052839896     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489111796887837     Document Type: Erratum

References (142)

1. Hawrelak JA, Myers SP. The causes of intestinal dysbiosis: A review. Altern Med Rev 2004; 9: 180-97.
2. Salminen S, Bouley C, Boutron-Ruault MC, Cummings JH, Franck A, Gibson GR, et al. Functional food science and gastrointestinal physiology and function. Br J Nutr 1998; 80 (Suppl 1): S147-S171.
3. Mowat AM. Dendritic cells and immune responses to orally administered antigens. Vaccine 2005; 23: 1797-9.
4. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005; 307: 1920-5.
5. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007; 117: 514-21.
6. Atreya R, Neurath MF. Chemokines in inflammatory bowel diseases. Dig Dis 2010; 28: 386-94.
7. Klapproth JM, Sasaki M. Bacterial induction of proinflammatory cytokines in inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 2173-9.
8. Choudhry MA, Rana SN, Kavanaugh MJ, Kovacs EJ, Gamelli RL, Sayeed MM. Impaired intestinal immunity and barrier function: A cause for enhanced bacterial translocation in alcohol intoxication and burn injury. Alcohol 2004; 33: 199-208.
9. Choudhry MA, Chaudry IH. Alcohol, burn injury, and the intestine.J Emerg Trauma Shock 2008; 1: 81-7.
10. Akhtar S, Li X, Chaudry IH, Choudhry MA. Neutrophil chemoki-nes and their role in IL-18-mediated increase in neutrophil O2- production and intestinal edema following alcohol intoxication and burn injury. Am J Physiol Gastrointest Liver Physiol 2009; 297: G340-G347.
11. Bemis, G.W., Salituro, F.G., Duffy, J.P., Harrington, E.M. Inhibitors of p38. US6147080 (2000).
12. Hale, M., Janetka, J., Maltais, F., Cao, J., Mashal, R. Isoxazole compositions useful as inhibitors of ERK. US6495582 (2002).
13. Bonny, C. Cell-permeable peptide inhibitors of the JNK signal transduction pathway. US6780970 (2004).
14. Douangpanya, J., Hayflick, J.S., Puri, K.D. Novel PI3K delta inhibitors and methods of use thereof. US20100029693 (2010).
15. Harnish, D.C., Chadwick, C.C., Keith, J.C. Methods of treating inflammatory bowel disease using NF-kB inhibitors. US20050119276 (2005).
16. Bakker, A., Duguay, A.N., Liu, Q., Silverman, J., Moore, K. IL-6 binding proteins. US7820790 (2010).
17. Ghayur, T., Labkovsky, B., Voss, J.W., Green, L., Babcook, J., Jia, X., Wieler, J., Kang, J.S., Hedberg, B. IL-18 binding proteins. US20100291088 (2010).
18. Watkins, J.D., Vasserot, A.P., Marquis, D., Huse, W.D. TNF-alpha binding proteins. US20060269549 (2006).
19. Das, A., Carton, J.M. Anti-MCP-1 antibodies, compositions, methods and uses. US20060039913 (2006).
20. Faanes, R.B., McGoff, P.E., Shirley, B.A., Scher, D.S. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation. US5695760 (1997).
21. Meng, C.Q. Compounds and methods for the inhibition of the expression of VCAM-1. US20020188118 (2002).
22. Moyle, M., Foster, D.L., Vlasuk, G.P. Neutrophil inhibitors. US6818616 (2004).
23. Traynor-Kaplan, A.E., Schultz, C., Rudolf, M.T. Inositol derivatives for inhibiting superoxide anion production. US6221856 (2001).
24. Devy, L., Buckler, D., Cohen, E.H. Metalloproteinase 9 binding proteins. US20090311245 (2009).
25. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010; 1802: 396-405.
26. Hollenbach E, Neumann M, Vieth M, Roessner A, Malfertheiner P, Naumann M. Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease. FASEB J 2004; 18: 1550-2.
27. Zhou Y, Wang Q, Mark EB, Chung DH. Oxidative stress-induced intestinal epithelial cell apoptosis is mediated by p38 MAPK. Bio-chem Biophys Res Commun 2006; 350: 860-5.
28. Zheng SY, Fu XB, Xu JG, Zhao JY, Sun TZ, Chen W. Inhibition of p38 mitogen-activated protein kinase may decrease intestinal epithelial cell apoptosis and improve intestinal epithelial barrier function after ischemia-reperfusion injury. World J Gastroenterol 2005; 11: 656-60.
29. Choudhry MA, Chaudry IH. Alcohol, burn injury, and the intestine. J Emerg Trauma Shock 2008; 1: 81-7.
30. Costantini TW, Peterson CY, Kroll L, Loomis WH, Eliceiri BP, Baird A, et al. Role of p38 MAPK in burn-induced intestinal barrier breakdown. J Surg Res 2009; 156: 64-9.
31. Costantini TW, Peterson CY, Kroll L, Loomis WH, Eliceiri BP, Baird A, et al. Role of p38 MAPK in burn-induced intestinal barrier breakdown. J Surg Res 2009; 156: 64-9.
32. Huang FC. Upregulation of Salmonella-induced IL-6 production in Caco-2 cells by PJ-34, PARP-1 inhibitor: involvement of PI3K, p38 MAPK, ERK, JNK, and NF-kappaB. Mediators Inflamm 2009; 2009: 103890.
33. Ihara E, Beck PL, Chappellaz M, Wong J, Medlicott SA, Mac-Donald JA. Mitogen-activated protein kinase pathways contribute to hypercontractility and increased Casup2+/sup sensitization in murine experimental colitis. Mol Pharmacol 2009; 75: 1031-41.
34. Li HH, Fu XB, Sun TZ, Cai CL, Zhou G, Chen W, et al. Non-mitogenic acidic fibroblast growth factor reduces intestinal dysfunction induced by ischemia and reperfusion injury in rats. J Gas-troenterol Hepatol 2007; 22: 363-70.
35. Costantini TW, Peterson CY, Kroll L, Loomis WH, Putnam JG, Wolf P, et al. Burns, inflammation, and intestinal injury: Protective effects of an anti-inflammatory resuscitation strategy. J Trauma 2009; 67: 1162-8.
36. Clark JA, Coopersmith CM. Just the right amount of JNK: How nuclear factor-kappaB and downstream mediators prevent burn-induced intestinal injury. Crit Care Med 2007; 35: 1433-4.
37. Chen LW, Chen PH, Chang WJ, Wang JS, Karin M, Hsu CM. IKappaB-kinase/nuclear factor-kappaB signaling prevents thermal injury-induced gut damage by inhibiting c-Jun NH2-terminal kinase activation. Crit Care Med 2007; 35: 1332-40.
38. Choi EY, Hwang HJ, Nam TJ. Protective effect of a polysaccharide from Hizikia fusiformis against ethanol-induced cytotoxicity in IEC-6 cells. Toxicol In Vitro 2010; 24: 79-84.
39. da Silva MS, Sanchez-Fidalgo S, Talero E, Cardeno A, da Silva MA, Villegas W, et al. Anti-inflammatory intestinal activity of Abarema cochliacarpos (Gomes) Barneby & Grimes in TNBS colitis model. J Ethnopharmacol 2010; 128: 467-75.
40. Gunther R, Kishore PN, Abbas HK, Mirocha CJ. Immunosuppres-sive effects of dietary wortmannin on rats and mice. Immunophar-macol Immunotoxicol 1989; 11: 559-70.
41. Gunther R, Abbas HK, Mirocha CJ. Acute pathological effects on rats of orally administered wortmannin-containing preparations and purified wortmannin from Fusarium oxysporum. Food Chem Toxi-col 1989; 27: 173-9.
42. Sheng H, Shao J, Townsend CM, Jr., Evers BM. Phosphatidylinosi-tol 3-kinase mediates proliferative signals in intestinal epithelial cells. Gut 2003; 52: 1472-8.
43. Chen SD, Chen YB, Peng Y, Xu J, Chen SS, Zhang JL, et al. Role of PI3K/Akt signaling in the protective effect of magnesium sulfate against ischemia-perfusion injury of small intestine in rats. Chin Med J (Engl) 2010; 123: 1447-52.
44. Babbin BA, Jesaitis AJ, Ivanov AI, Kelly D, Laukoetter M, Nava P, et al. Formyl peptide receptor-1 activation enhances intestinal epithelial cell restitution through phosphatidylinositol 3-kinase-dependent activation of RaC1 and Cdc42. J Immunol 2007; 179: 8112-21.
45. Dagia NM, Agarwal G, Kamath DV, Chetrapal-Kunwar A, Gupte RD, Jadhav MG, et al. A preferential p110alpha/gamma PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-kappaB-dependent manner. Am J Physiol Cell Physiol 2010; 298: C929-C941.
46. Dagia NM, Agarwal G, Kamath DV, Chetrapal-Kunwar A, Gupte RD, Jadhav MG, et al. A preferential p110alpha/gamma PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-kappaB-dependent manner. Am J Physiol Cell Physiol 2010; 298: C929-C941.
47. Van Dop WA, Marengo S, Te Velde AA, Ciraolo E, Franco I, Ten Kate FJ, et al. The absence of functional PI3Kgamma prevents leukocyte recruitment and ameliorates DSS-induced colitis in mice. Immunol Lett 2010; 131: 33-9.
48. Lee G, Goretsky T, Managlia E, Dirisina R, Singh AP, Brown JB, et al. Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology 2010; 139: 869-81, 881.
49. Shao J, Evers BM, Sheng H. Roles of phosphatidylinositol 3'-kinase and mammalian target of rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 2004; 64: 229-35.
50. Liu X, Powlas J, Shi Y, Oleksijew AX, Shoemaker AR, De JR, et al. Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth. Anticancer Res 2004; 24: 2697-704.
51. Gunther R, Abbas HK, Mirocha CJ. Acute pathological effects on rats of orally administered wortmannin-containing preparations and purified wortmannin from Fusarium oxysporum. Food Chem Toxi-col 1989; 27: 173-9.
52. Matzke MA, Birchler JA. RNAi-mediated pathways in the nucleus. Nat Rev Genet 2005; 6: 24-35.
53. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008; 132: 344-62.
54. Dijkstra G, Moshage H, Jansen PL. Blockade of NF-kappaB activation and donation of nitric oxide: New treatment options in inflammatory bowel disease? Scand J Gastroenterol Suppl 2002; 37-41.
55. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 1998; 42: 477-84.
56. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998; 115: 357-69.
57. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastro-enterol 2008; 14: 4280-8.
58. Chen LW, Egan L, Li ZW, Greten FR, Kagnoff MF, Karin M. The two faces of IKK and NF-kappaB inhibition: Prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 2003; 9: 575-81.
59. Chen LW, Chen PH, Chang WJ, Wang JS, Karin M, Hsu CM. IKappaB-kinase/nuclear factor-kappaB signaling prevents thermal injury-induced gut damage by inhibiting c-Jun NH2-terminal kinase activation. Crit Care Med 2007; 35: 1332-40.
60. Sun BW, Jin Q, Sun Y, Sun ZW, Chen X, Chen ZY, et al. Carbon liberated from CO-releasing molecules attenuates leukocyte infiltration in the small intestine of thermally injured mice. World J Gastroenterol 2007; 13: 6183-90.
61. Zhou W, Cao Q, Peng Y, Zhang QJ, Castrillon DH, DePinho RA, et al. FoxO4 inhibits NF-kappaB and protects mice against colonic injury and inflammation. Gastroenterology 2009; 137: 1403-14.
62. Faist E, Schinkel C, Zimmer S. Update on the mechanisms of immune suppression of injury and immune modulation. World J Surg 1996; 20: 454-9.
63. Messingham KA, Faunce DE, Kovacs EJ. Alcohol, injury, and cellular immunity. Alcohol 2002; 28: 137-49.
64. Miller-Graziano CL, De AK, Kodys K. Altered IL-10 levels in trauma patients' M phi and T lymphocytes. J Clin Immunol 1995; 15: 93-104.
65. Schwacha MG, Chaudry IH. The cellular basis of post-burn immu-nosuppression: Macrophages and mediators. Int J Mol Med 2002; 10: 239-43.
66. Yao YM, Redl H, Bahrami S, Schlag G. The inflammatory basis of trauma/shock-associated multiple organ failure. Inflamm Res 1998; 47: 201-10.
67. Kishimoto T. Interleukin-6: From basic science to medicine-40 years in immunology. Annu Rev Immunol 2005; 23: 1-21.
68. Kishimoto T. IL-6: From its discovery to clinical applications. Int Immunol 2010; 22: 347-52.
69. Huber NL, Bailey SR, Schuster RM, Ogle CK, Lentsch AB, Pritts TA. Remote thermal injury increases LPS-induced intestinal IL-6 production. J Surg Res 2010; 160: 190-5.
70. Yang R, Han X, Uchiyama T, Watkins SK, Yaguchi A, Delude RL, et al. IL-6 is essential for development of gut barrier dysfunction after hemorrhagic shock and resuscitation in mice. Am J Physiol Gastrointest Liver Physiol 2003; 285: G621-G629.
71. Scalfani MT, Chan DM, Murdoch EL, Kovacs EJ, White FA. Acute ethanol exposure combined with burn injury enhances IL-6 levels in the murine ileum. Alcohol Clin Exp Res 2007; 31: 1731-7.
72. Hegazy SK, El-Bedewy MM. Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol 2010; 16: 4145-51.
73. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003; 73: 213-24.
74. Akhtar S, Li X, Kovacs EJ, Gamelli RL, Choudhry MA. Interleu-kin-18 Delays neutrophil apoptosis following alcohol intoxication and burn injury. Mol Med 2010.
75. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-32.
76. Van d, V, Netea MG, Dinarello CA, Joosten LA. Inflammasome activation and IL-1beta and IL-18 processing during infection. Trends Immunol 2011; 32: 110-6.
77. Stutz A, Golenbock DT, Latz E. Inflammasomes: Too big to miss. J Clin Invest 2009; 119: 3502-11.
78. Li X, Kovacs EJ, Schwacha MG, Chaudry IH, Choudhry MA. Acute alcohol intoxication increases interleukin-18-mediated neu-trophil infiltration and lung inflammation following burn injury in rats. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1193-L1201.
79. Rana SN, Li X, Chaudry IH, Bland KI, Choudhry MA. Inhibition of IL-18 reduces myeloperoxidase activity and prevents edema in intestine following alcohol and burn injury. J Leukoc Biol 2005; 77: 719-28.
80. Ng J, Hirota SA, Gross O, Li Y, Ulke-Lemee A, Potentier MS, et al. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology 2010; 139: 542-52, 552.
81. Li X, Rana SN, Schwacha MG, Chaudry IH, Choudhry MA. A novel role for IL-18 in corticosterone-mediated intestinal damage in a two-hit rodent model of alcohol intoxication and injury. J Leu-koc Biol 2006; 80: 367-75.
82. Sivakumar PV, Westrich GM, Kanaly S, Garka K, Born TL, Derry JM, et al. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: Blocking interleukin 18 attenuates intestinal damage. Gut 2002; 50: 812-20.
83. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666-70.
84. Morgan MJ, Liu ZG. Reactive oxygen species in TNFalpha-induced signaling and cell death. Mol Cells 2010; 30: 1-12.
85. Kozuch PL, Hanauer SB. General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin North Am 2006; 35: 757-73.
86. Grootjans J, Lenaerts K, Derikx JP, Matthijsen RA, de Bruine AP, van Bijnen AA, et al. Human intestinal ischemia-reperfusion-induced inflammation characterized: Experiences from a new trans-lational model. Am J Pathol 2010; 176: 2283-91.
87. Chen LW, Huang HL, Lee IT, Hsu CM, Lu PJ. Thermal injury-induced priming effect of neutrophil is TNF-alpha and P38 dependent. Shock 2006; 26: 69-76.
88. Costantini TW, Loomis WH, Putnam JG, Drusinsky D, Deree J, Choi S, et al. Burn-induced gut barrier injury is attenuated by phosphodiesterase inhibition: Effects on tight junction structural proteins. Shock 2009; 31: 416-22.
89. Alcami A, Lira SA. Modulation of chemokine activity by viruses. Curr Opin Immunol 2010; 22: 482-7.
90. Mackay CR. Chemokines: Immunology's high impact factors. Nat Immunol 2001; 2: 95-101.
91. Banks C, Bateman A, Payne R, Johnson P, Sheron N. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 2003; 199: 28-35.
92. Mazzucchelli L, Hauser C, Zgraggen K, Wagner H, Hess M, Lais-sue JA, et al. Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. Am J Pathol 1994; 144: 997-1007.
93. Banks C, Bateman A, Payne R, Johnson P, Sheron N. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 2003; 199: 28-35.
94. Reinecker HC, Loh EY, Ringler DJ, Mehta A, Rombeau JL, MacDermott RP. Monocyte-chemoattractant protein 1 gene expression in intestinal epithelial cells and inflammatory bowel disease mucosa. Gastroenterology 1995; 108: 40-50.
95. Krieglstein CF, Granger DN. Adhesion molecules and their role in vascular disease. Am J Hypertens 2001; 14: 44S-54S.
96. Bernstein CN, Sargent M, Gallatin WM. Beta2 integrin/ICAM expression in Crohn's disease. Clin Immunol Immunopathol 1998; 86: 147-60.
97. Burns RC, Rivera-Nieves J, Moskaluk CA, Matsumoto S, Cominelli F, Ley K. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology 2001; 121: 1428-36.
98. Martinesi M, Treves C, Bonanomi AG, Milla M, Bagnoli S, Zuegel U, et al. Down-regulation of adhesion molecules and matrix metal-loproteinases by ZK 156979 in inflammatory bowel diseases. Clin Immunol 2010; 136: 51-60.
99. Wu DM, Duan WQ, Liu Y, Cen Y. Anti-inflammatory effect of the polysaccharides of golden needle mushroom in burned rats. Int J Biol Macromol 2010; 46: 100-3.
100. Adamska I, Czerwionka-Szaflarska M, Kulwas A, Mierzwa G, Bala G, Rosc D. [Value of E-selectin and L-selectin determination in children and youth with inflammatory bowel disease]. Med Wieku Rozwoj 2007; 11: 413-8.
101. Asaduzzaman M, Mihaescu A, Wang Y, Sato T, Thorlacius H. P-selectin and P-selectin glycoprotein ligand 1 mediate rolling of activated CD8+ T cells in inflamed colonic venules. J Investig Med 2009; 57: 765-8.
102. Yoshida N, Yamaguchi T, Nakagawa S, Nakamura Y, Naito Y, Yoshikawa T. Role of P-selectin and intercellular adhesion mole-cule-1 in TNB-induced colitis in rats. Digestion 2001; 63 Suppl 1: 81-6.
103. Maianski NA, Maianski AN, Kuijpers TW, Roos D. Apoptosis of neutrophils. Acta Haematol 2004; 111: 56-66.
104. Akgul C, Moulding DA, Edwards SW. Molecular control of neu-trophil apoptosis. FEBS Lett 2001; 487: 318-22.
105. Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol 1997; 61: 375-80.
106. Li X, Schwacha MG, Chaudry IH, Choudhry MA. Acute alcohol intoxication potentiates neutrophil-mediated intestinal tissue damage after burn injury. Shock 2008; 29: 377-83.
107. Medina C, Radomski MW. Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther 2006; 318: 933-8.
108. Li X, Schwacha MG, Chaudry IH, Choudhry MA. Heme oxy-genase-1 protects against neutrophil-mediated intestinal damage by down-regulation of neutrophil p47phox and p67phox activity and O2- production in a two-hit model of alcohol intoxication and burn injury. J Immunol 2008; 180: 6933-40.
109. Sayeed MM. Exuberant Ca(2+) Signaling in Neutrophils: A Cause for Concern. News Physiol Sci 2000; 15: 130-6.
110. Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease-radicals or ridiculous? Aliment Pharmacol Ther 2002; 16: 1997-2015.
111. Simmonds NJ, Allen RE, Stevens TR, Van Someren RN, Blake DR, Rampton DS. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterol-ogy 1992; 103: 186-96.
112. Igarashi R, Hoshino J, Ochiai A, Morizawa Y, Mizushima Y. Leci-thinized superoxide dismutase enhances its pharmacologic potency by increasing its cell membrane affinity. J Pharmacol Exp Ther 1994; 271: 1672-7.
113. Ishihara T, Tanaka K, Tasaka Y, Namba T, Suzuki J, Ishihara T, et al. Therapeutic effect of lecithinized superoxide dismutase against colitis. J Pharmacol Exp Ther 2009; 328: 152-64.
114. Nagase H, Woessner JF, Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
115. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
116. Medina C, Radomski MW. Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther 2006; 318: 933-8.
117. Medina C, Radomski MW. Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther 2006; 318: 933-8.
118. Naito Y, Takagi T, Kuroda M, Katada K, Ichikawa H, Kokura S, et al. An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice. In-flamm Res 2004; 53: 462-8.
119. Pirila E, Ramamurthy NS, Sorsa T, Salo T, Hietanen J, Maisi P. Gelatinase A (MMP-2), collagenase-2 (MMP-8), and laminin-5 gamma2-chain expression in murine inflammatory bowel disease (ulcerative colitis). Dig Dis Sci 2003; 48: 93-8.
120. Medina C, Radomski MW. Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther 2006; 318: 933-8.
121. Naito Y, Yoshikawa T. Role of matrix metalloproteinases in inflammatory bowel disease. Mol Aspects Med 2005; 26: 379-90.
122. Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999; 117: 814-22.
123. Delclaux C, Delacourt C, D'Ortho MP, Boyer V, Lafuma C, Harf A. Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am J Respir Cell Mol Biol 1996; 14: 288-95.
124. Medina C, Radomski MW. Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther 2006; 318: 933-8.
125. Castaneda FE, Walia B, Vijay-Kumar M, Patel NR, Roser S, Kolachala VL, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: Central role of epithelial-derived MMP. Gastroenterology 2005; 129: 1991-2008.
126. Medina C, Videla S, Radomski A, Radomski MW, Antolin M, Guarner F, et al. Increased activity and expression of matrix metal-loproteinase-9 in a rat model of distal colitis. Am J Physiol Gastro-intest Liver Physiol 2003; 284: G116-G122.
127. Clarke TB, Davis KM, Lysenko ES, Zhou AY, Yu Y, Weiser JN. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med 2010; 16: 228-31.
128. Mazmanian SK, Kasper DL. The love-hate relationship between bacterial polysaccharides and the host immune system. Nat Rev Immunol 2006; 6: 849-58.
129. Wells JM, Rossi O, Meijerink M, Van BP. Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci USA 2011; 108 Suppl 1: 4607-14.
130. Bode JC, Bode C, Heidelbach R, Durr HK, Martini GA. Jejunal microflora in patients with chronic alcohol abuse. Hepatogastroen-terology 1984; 31: 30-4.
131. Diamant M, Blaak EE, de Vos WM. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? Obes Rev 2011; 12: 272-81.
132. Ohland CL, Macnaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 2010; 298: G807-G819.
133. Choudhry MA, Li X, Chaudry IH. A role for corticosterone in impaired intestinal immunity and barrier function in a rodent model of acute alcohol intoxication and burn injury. J Neuroimmune Pharmacol 2006; 1: 428-34.
134. Deitch EA. Gut lymph and lymphatics: A source of factors leading to organ injury and dysfunction. Ann N Y Acad Sci 2010; 1207 (Suppl 1): E103-E111.
135. Choudhry MA, Fazal N, Goto M, Gamelli RL, Sayeed MM. Gut-associated lymphoid T cell suppression enhances bacterial translo-cation in alcohol and burn injury. Am J Physiol Gastrointest Liver Physiol 2002; 282: G937-G947.
136. Ambrose NS, Johnson M, Burdon DW, Keighley MR. Incidence of pathogenic bacteria from mesenteric lymph nodes and ileal serosa during Crohn's disease surgery. Br J Surg 1984;71: 623-5.
137. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118: 229-41.
138. Franchi L, Munoz-Planillo R, Reimer T, Eigenbrod T, Nunez G. Inflammasomes as microbial sensors. Eur J Immunol 2010; 40: 611-5.
139. De-Souza DA, Greene LJ. Intestinal permeability and systemic infections in critically ill patients: effect of glutamine. Crit Care Med 2005; 33: 1125-35.
140. Xia XM, Wang FY, Xu WA, Wang ZK, Liu J, Lu YK, et al. CXCR4 antagonist AMD3100 attenuates colonic damage in mice with experimental colitis. World J Gastroenterol 2010; 16: 2873-80.
141. Johansson ME, Gustafsson JK, Sjoberg KE, Petersson J, Holm L, Sjovall H, et al. Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model. PLoS One 2010; 5: e12238.
142. Feinman R, Deitch EA, Watkins AC, Abungu B, Colorado I, Kannan KB, et al. HIF-1 mediates pathogenic inflammatory responses to intestinal ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2010; 299: G833-G843.